Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Biopharmaceutical company reports loss of $0.09 per share
June 6th, 2005
ImmunoGen, Inc., (IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, announced financial results for the 3- and 9-month periods ended March 31, 2005, - the third quarter and first 9 months, respectively, of the company's 2005 fiscal year. For the 3-month period ended March 31, 2005, the company reported a net loss of $3.6 million, or $0.09 per basic and diluted share, compared to a net loss of $0.8 million, or $0.02 per basic and diluted share, for the same period last year. For the 9-month period ended March 31, 2005, the company reported a net loss of $8.2 million,...
Source: Biotech Business Week (2005-06-06)
|
